Both Pfizer’s Paxlovid and Merck’s molnupiravir are cleared for emergency use in non-hospitalized people who have mild-to-moderate symptoms and are at heightened risk of developing severe disease. Peter Anderson, PharmD spoke with Health regarding their effectiveness.